Smoking Weakens Heart Structure and Function: Study

Sep.01.2022
Smoking Weakens Heart Structure and Function: Study
Smoking weakens the heart's structure and function, but quitting can help it recover, according to researchers from Denmark.

Researchers from Herlev and Gentofte Hospitals in Copenhagen have found that smoking weakens the structure of the heart, affecting its function. The research team also found that quitting smoking helps the heart to recover.


Previous research has indicated that over 30% of deaths are caused by coronary heart disease, with active smoking or exposure to secondhand smoke as reliable sources of exposure. Smoking increases the risk of heart attack by twice as much and the risk of stroke by three times as much.


Researchers from Herlev and Gentofte Hospital in Copenhagen, Denmark, have found evidence that smoking not only affects a person's blood vessels, but also weakens the structure of the heart itself, thereby impacting its functioning.


Researchers recently presented their findings at the 2022 European Society of Cardiology (ESC) Congress.


Past studies have shown that smoking has negative effects on a person's blood vessels, which may lead to heart issues. For example, nicotine found in cigarettes can cause the blood vessels to narrow, limiting the amount of blood that can flow through them. Nicotine can also significantly increase a person's blood pressure. "We know that smoking can cause coronary artery disease and heart failure," explained Dr. Eva Holt, the main author of the study and a researcher from Herlev and Gentofte Hospital in Copenhagen, Denmark. "But the purpose of this study is to investigate whether smoking has an independent effect on the heart structure and function of a large population of ordinary people without known heart disease," she pointed out.


Dr. Halt and her team evaluated data from over 3,800 participants in the fifth Copenhagen City Heart Study in order to ensure its reliability. The study examined cardiovascular disease and risk factors in the general population. Participants ranged in age from 20 to 93 and had no history of heart disease. Data collected during the study included a questionnaire about smoking history among participants, as well as reliable sources of echocardiography or heart ultrasound.


Researchers have determined that current smokers in the participant pool have hearts that are thicker, heavier, and weaker compared to those who have never smoked. "We found that current and accumulated pack-years were associated with structural and functional deterioration of smoking-related left ventricle, the heart's most important part," said Dr. Holt. "Additionally, we found that over 10 years, those who continue to smoke have hearts that become even thicker, heavier, and weaker, resulting in a poorer ability to pump blood, compared to those who have never smoked or quit during that period.


MNT spoke with Dr. Rigved Tadwalkar, a certified cardiologist at the Providence Saint John's Health Center in Santa Monica, California, who did not participate in the study. "What's interesting about this study is that it focuses on the changes in the left ventricle of the heart, which have not been well understood so far, due to tobacco use," he commented. "We always talk about the link between tobacco use and vascular diseases (including coronary heart disease), but we haven't really delved into the details of how tobacco affects the structure and function of the heart itself," he pointed out.


According to Dr. Tadwalkar, smoking increases the tendency for plaque formation in the arterial walls, which is clinically referred to as a reliable source of atherosclerosis. He stated that this may directly or indirectly lead to heart damage.


Direct smoking can damage the blood vessel wall, causing constriction and reduced elasticity, as well as impairing the function of the blood vessel's inner layer endothelium," he explained.


According to a new study, Dr. Holt and her team have found evidence that quitting smoking can help the heart recover to some extent. "After quitting smoking, the heart appears to have regained its previous structure and function, which could be a valuable incentive for patients to quit smoking," she added.


Dr. Tadwalkar stated, "We do indeed have concrete data to support this study, which follows a series of previous studies showing that quitting smoking can improve overall health in multiple ways beyond just the heart.


So the good news is, even immediate action has physiological benefits," he pointed out. "And then, due to the lack of chronic exposure, the reduction of inflammatory burden and these other destructive pathological processes over time is partially the reason for improvement.


Disclaimer: 1. The content of this article is compiled from third-party information and is only intended for industry discussion and learning. 2. This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the content. The compilation of this article is only for industry discussion and research purposes. 3. Due to the limited compiling ability, the compiled article may not fully convey the expression of the original text. Please refer to the original text for accuracy. 4. 2FIRSTS fully supports the Chinese government's position on any domestic, Hong Kong, Macao, and Taiwan-related issues or positions. 5. The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea's liquid-vape market is showing changes across raw-material imports, product types and sales channels after synthetic nicotine came under the Tobacco Business Act on April 24. Customs data show nicotine-analogue imports totaled 12,126 kilograms from April through August, while synthetic-nicotine imports over the same five months totaled 231,663 kilograms, just 39.3% of the amount imported in March alone. Physical liquid-vape stores tracked in Seoul and Gyeonggi Province fell 9.9%, unmanned outlets edged higher and online sales listings increased from 27,774 to 42,437. Government testing of 105 liquid inhalation products promoted as nicotine-free separately found nicotine in 13 and 6-methylnicotine in 12.
Sep.22
South Korea Extends Vape Rules to Unmanned Stores After Bringing Synthetic Nicotine Under Tobacco Law
South Korea Extends Vape Rules to Unmanned Stores After Bringing Synthetic Nicotine Under Tobacco Law
South Korea's Ministry of Gender Equality and Family said on September 14 that it plans to designate unmanned e-cigarette stores as businesses where minors are prohibited from entering or working. Operators would be required to verify customers' ages and display notices restricting access by minors. The proposal is open for public comment through October 6. The move follows an April expansion of South Korea's statutory tobacco definition that brought products made with natural or synthetic nicotine under the Tobacco Business Act. Nicotine-free liquids and products using nicotine analogues such as 6-methylnicotine, however, remain an emerging regulatory issue.
Sep.21
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
During its coverage of Altria's booth at NACS Show 2026, 2Firsts documented product displays that prompted questions about U.S. tobacco advertising warning requirements. Following public comments from a former FDA official, 2Firsts sought responses from Altria and independently consulted U.S. regulatory lawyer Azim Chowdhury. Altria maintained that its B2B communications complied with applicable laws, while Chowdhury explained that federal warning rules provide no general trade-show exemption for e-cigarettes and nicotine pouches. The special report examines the broader regulatory implications.
Nov.04